Does ADT benefit unfavourable intermediate risk prostate cancer patients treated with brachytherapy boost and external beam radiotherapy? A propensity-score matched analysis.
CONCLUSION: Short-term ADT increased BFFS in UIR prostate cancer patients treated with HDR-BT boost plus EBRT.
PMID: 32619455 [PubMed - as supplied by publisher]
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Mendez LC, Martell K, Warner A, Tseng CL, Chung H, Loblaw A, Rodrigues GB, Morton G Tags: Radiother Oncol Source Type: research
More News: Brachytherapy | Cancer | Cancer & Oncology | External Beam Therapy | Men | Prostate Cancer | Radiology